No Data
ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities
ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22
Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts Target Price to $26 From $30
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability